|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma显示文摘AIM: To evaluate the outcome predictors of percu- taneous ablation therapy in patients with unresectable hepatocellular carcinoma (HCC), especially to identify whether the initial treatment response contributes to the survival of the patients. METHODS: The study cohort included 153 patients with single (102) and two or three (51) HCC nodules 5 cm or less in maximum diameter. As an initial treatment, 110 patients received radiofrequency ablation and 43 patients received percutaneous ethanol injection. RESULTS: The Kaplan-Meier estimates of overall 3- and 5-year survival rates were 75% and 59%, respectively. The log-rank test revealed statistically significant differences in the overall survivals according to Child- Pugh class (P = 0.0275), tumor size (P = 0.0130), serum albumin level (P = 0.0060), serum protein induced by vitamin K absence or antagonist Ⅱ level (P = 0.0486), and initial treatment response (P = 0.0130). The independent predictors of survival were serum albumin level (risk ratio, 3.216; 95% CI, 1.407-7.353; P = 0.0056) and initial treatment response (risk ratio, 2.474; 95% CI, 1.076-5.692; P = 0.0330) based on the Cox proportional hazards regression models. The patients had a serum albumin level 3.5 g/dL and the 3- and 5-year survival rates of 86% and 82%. CONCLUSION: In HCC patients treated with percutaneous ablation therapy, serum albumin level and initial treatment response are the independent outcome predictors. | Manabu Morimoto Kazushi Numata Kazuya Sugimori Kazuhito Shirato Atsushi Kokawa Hiroyuki Oka Kingo Hirasawa Ryonho Koh Hiromi Nihommatsu Katsuaki Tanaka | 2007 | World Journal of Gastroenterology2007，13，7： | 8 |
| 2 | Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms显示文摘 | Ryonho Koh Kingo Hirasawa Sei Yahara Hiroyuki Oka Kazuya Sugimori Manabu Morimoto Kazushi Numata Atsushi Kokawa Takeshi Sasaki Akinori Nozawa Masataka Taguri Satoshi Morita Shin Maeda Katsuaki Tanaka | 2013 | Gastrointestinal Endoscopy2013，，： | 2 |
| 3 | Quantitative analysis of alcohol–water binary solutions using Raman spectroscopy显示文摘 | Yasushi Numata Yoshiyuki Iida Hiroyuki Tanaka | 2011 | Journal of Quantitative Spectroscopy and Radiative Transfer2011，，6： | 1 |
| 4 | Performance of a closed recirculating system with foam separation, nitrification and denitrification units for intensive culture of eel: towards zero emission 显示文摘 | Yoshihiro Suzuki Toshiroh Maruyama Hiroyuki Numata | 2003 | Aquacult Eng2003，29，3： | 1 |
| 5 | Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma显示文摘AIM To evaluate whether pathologically early hepatocellular carcinoma(HCC) exhibited local tumor progression after radiofrequency ablation(RFA) less often than typical HCC.METHODS Fifty pathologically early HCCs [tumor diameter(mm): mean, 15.8; range, 10-23; follow-up days after RFA: median, 1213; range, 216-2137] and 187 typical HCCs [tumor diameter(mm): mean, 15.6; range, 6-30; follow-up days after RFA: median, 1116; range, 190-2328] were enrolled in this retrospective study. The presence of stromal invasion(namely, tumor cell invasion into the intratumoral portal tracts) was considered to be the most important pathologic finding for the diagnosis of early HCCs. Typical HCC was defined as the presence of a hyper-vascular lesion accompanied by delayed washout using contrastenhanced computed tomography or contrast-enhanced magnetic resonance imaging. Follow-up examinations were performed at 3-mo intervals to monitor for signs of local tumor progression. The local tumor progression rates of pathologically early HCCs and typical HCCs were then determined using the Kaplan-Meier method.RESULTS During the follow-up period for the 50 pathologically early HCCs, 49(98%) of the nodules did not exhibit local tumor progression. However, 1 nodule(2%) was associated with a local tumor progression found 636 d after RFA. For the 187 typical HCCs, 46(24.6%) of the nodules exhibited local recurrence after RFA. The follow-up period until the local tumor progression of typical HCC was a median of 605 d, ranging from 181 to 1741 d. Among the cases with typical HCCs, local tumor progression had occurred in 7.0%(7/187), 16.0%(30/187), 21.9%(41/187) and 24.6%(46/187) of the cases at 1, 2, 3 and 4 years, respectively. Pathologically early HCC was statistically associated with a lower rate of local tumor progression, compared with typical HCC, when evaluated using a log-rank test(P = 0.002). CONCLUSION The rate of local tumor progression for pathologically early HCCs after RFA was significantly lower than that for typical HCCs. | Yoshiteru Hao Kazushi Numata Tomohiro Ishii Hiroyuki Fukuda Shin Maeda Masayuki Nakano Katsuaki Tanaka | 2017 | World Journal of Gastroenterology2017，23，17： | 1 |
| 6 | Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer显示文摘 | Yoji Sanomura Shiro Oka Shinji Tanaka Norifumi Numata Makoto Higashiyama Hiroyuki Kanao Shigeto Yoshida Yoshitaka Ueno Kazuaki Chayama | 2014 | Gastric Cancer2014，，： | 1 |
| 7 | Lenvatinib for large hepatocellular carcinomas with portal trunk invasion:Two case reports显示文摘BACKGROUND In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma(uHCC),the drug proved non-inferior to sorafenib in terms of the overall survival,but offered better progression-free survival.However,the effects of lenvatinib in uHCC patients with a tumor thrombus in the main portal vein and/or a high tumor burden(tumor occupancy more than 50%of the total liver volume),remain unclear,because these were set as exclusion criteria in the aforementioned trial.CASE SUMMARY A 53-year-old man(case 1)and 66-year-old woman(case 2)with uHCC presented to us with a tumor thrombus in both the main portal vein and inferior vena cava,a high tumor burden accompanied by a tumor diameter greater than>100 mm,and distant metastasis,with the residual liver function classified as grade 2A according to the modified Albumin–Bilirubin grading.We started both patients on lenvatinib.The therapeutic effect,as evaluated by the modified Response Evaluation Criteria in Solid Tumors,was rated as partial response in both case 1 and case 2(at 8 wk and 4 wk after the start of lenvatinib administration,respectively).The therapeutic effect was sustained for 6 mo in case 1 and 20 mo in case 2.Fever occurred as an adverse event in both case 1 and 2,and hyperthyroidism and thrombocytopenia in only case 2,neither of which,however,necessitated treatment discontinuation.CONCLUSION Even in hepatocellular carcinoma patients with poor prognostic factors,if the liver function is well-preserved,lenvatinib is effective and safe. | Satoshi Komiyama Kazushi Numata Satoshi Moriya Hiroyuki Fukuda Makoto Chuma Shin Maeda | 2020 | World Journal of Clinical Cases2020，8，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员